| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.6 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.6 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.6 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |